As part of our program to develop breast cancer specific therapeutic agents , we have synthesized a conjugate agent that is a conjugate of the steroidal anti-estrogen and the potent cytotoxin doxorubicin .
In this effort , we employed a modular assembly approach to prepare a novel 11Î²-substituted steroidal anti-estrogen functionalized with an azido-tetraethylene glycol moiety , which could be coupled to a complementary doxorubicin benzoyl hydrazone functionalized with a propargyl tetraethylene glycol moiety .
Huisgen [ 3 + 2 ] cycloaddition chemistry gave the final hybrid that was evaluated for selective uptake and cytotoxicity in ER(+)-MCF-7 and ER(-)-MDA-MB-231 breast cancer cell lines .
The results demonstrated that the presence of the anti-estrogenic component in the hybrid compound was critical for selectivity and cytotoxicity in ER(+)-MCF-7 human breast cancer cells as the hybrid was more potent than doxorubicin in inhibition of cell proliferation and promoting cell death .
